{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 448119456
| IUPAC_name = 3-(aminosulfonyl)-4-phenoxy-5-pyrrolidin-1-ylbenzoic acid
| image = Piretanide structure.svg

<!--Clinical data-->
| tradename = Arelix, Eurelix, Tauliz
| Drugs.com = {{drugs.com|international|piretanide}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = ~90%<ref>{{cite book|last1=Mutschler|first1=Edited by Rainer F. Greger, H. Knauf, E. Mutschler|title=Diuretics. Handbook of Experimental Pharmacology (Том 117).|date=1995|publisher=Springer Science & Business Media, 2012|location=Berlin, Heidelberg|isbn=364279565X|pages=517}}</ref>
| protein_bound = 96%
| metabolism = not identified
| elimination_half-life = 
| excretion = Urine (60%), feces (40%)

<!--Identifiers-->
| IUPHAR_ligand = 4742
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 55837-27-9
| ATC_prefix = C03
| ATC_suffix = CA03
| ATC_supplemental =  
| PubChem = 4849
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank =  DB02925
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = DQ6KK6GV93
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01634
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 4683

<!--Chemical data-->
| chemical_formula =  
| C=17 | H=18 | N=2 | O=5 | S=1 
| molecular_weight = 362.40 g/mol
| smiles = NS(=O)(=O)c1c(Oc2ccccc2)c(N3CCCC3)cc(c1)C(=O)O
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = UJEWTUDSLQGTOA-UHFFFAOYSA-N
}}

'''Piretanide''' ([[International Nonproprietary Name|INN]], trade names '''Arelix''', '''Eurelix''', '''Tauliz''') has been synthesized in 1973 at [[Hoechst AG]] (Germany) as a [[loop diuretic]]<ref>{{Cite journal 
| last1 = Musini | first1 = V. M. 
| last2 = Wright | first2 = J. M. 
| last3 = Bassett | first3 = K. 
| last4 = Jauca | first4 = C. D. 
| editor1-last = Musini 
| editor1-first = Vijaya M 
| title = Blood pressure lowering efficacy of loop diuretics for primary hypertension 
| doi = 10.1002/14651858.CD003825.pub2 

| journal = The Cochrane Library
| issue = 4 
| pages = CD003825 
| year = 2009 
| pmid = 19821314 
| pmc = 
}}</ref> compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups. Studies of piretanide in rats and dogs in comparison with other high-ceiling diuretics such as [[furosemide]] and [[bumetanide]] found a more suitable dose/response rate (regression line) and a more favourable sodium/potassium excretion ratio. These findings led eventually to clinical studies in man and finally to the introduction as a saluretic and antihypertensive<ref name="AustriaCodex">{{cite book|title=Austria-Codex|editor=Haberfeld, H|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=3-85200-196-X|language=German}}</ref> medication in Germany, France, Italy and other countries.

==References==
{{Reflist}}

*W.Merkel, D.Bormann, D.Mania, R.Muschaweck and M.Hropot, Eur. J. Med. Chem.-Chim.Ther. 11,399 (1976).
*W.Merkel, D.Mania and D.Bormann, Liebigs Ann. Chem. 461 (1979).

{{Diuretics}}
{{Ionotropic glutamate receptor modulators}}

[[Category:Diuretics]]
[[Category:Pyrrolidines]]
[[Category:Phenol ethers]]
[[Category:Benzoic acids]]
[[Category:Carbonic anhydrase inhibitors]]
[[Category:NMDA receptor antagonists]]


{{cardiovascular-drug-stub}}